Testing citrate fluid safety during kidney filtration (CRRT)
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 3 study checks whether Prismocitrate 18 is safe for adults who need a kidney filtration treatment called CRRT. It is mainly for people who cannot safely use heparin (a common blood thinner) due to bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Be a candidate for CRRT (a machine-based kidney filtration treatment)
- Be expected to live at least 24 hours
- Have a reason you can’t use heparin safely, or you have a higher bleeding risk
- Have signed consent (you or your legal decision-maker)
- Not be allergic to citrate or have had citrate toxicity or related reactions before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a specific blood-thinning method using citrate works safely and effectively in critically ill patients whose kidneys have suddenly stopped working and need a special filtering machine. Researchers want to confirm that this approach prevents dangerous blood clots while keeping patients safe.
This study compares two ways to prevent blood clots during kidney dialysis in people with sepsis-related kidney failure. The goal is to see which method is safer and works better to keep the dialysis filter working properly.
This study looks at whether using the arm access (fistula or graft) that you already have for dialysis is safe and effective during continuous kidney replacement therapy (CRRT) in the ICU. It aims to see if this approach can work well for people who need dialysis while on a breathing machine.
This study looks at two different levels of dosing for continuous dialysis (CRRT) in patients with severe acute kidney injury in the ICU. It aims to find out which dose might be better for recovery.
This trial tests a special device that filters parts of the blood to calm inflammation in people with severe acute kidney injury in the ICU. It may help improve recovery and reduce complications by “deactivating” certain immune cells.
This study tests a special blood-filtering treatment for patients in the intensive care unit (ICU) with acute kidney injury. It uses a medicine called citrate to prevent blood clotting during dialysis, which may be safer for patients whose liver cannot process citrate normally.
Hear when a new Continuous Renal Replacement Therapy (CRRT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.